Sinopharm Group

Sinopharm Group Co., Ltd. is a Chinese pharmaceutical company. The parent company of Sinopharm Group was Sinopharm Industrial Investment, a 51–49 joint venture of state-owned enterprise China National Pharmaceutical Group and civilian-run enterprise Fosun Pharmaceutical.

Not to be confused with Sinopharm, the short name of the parent company China National Pharmaceutical Group.
Sinopharm Group
Typepublic
unlisted(A share)
SEHK: 1099(H share)
ISINCNE100000FN7
IndustryPharmaceutical
Founded
  • 1998 (predecessor)
  • 2003
FounderChina National Pharmaceutical Group
HeadquartersSinopharm Plaza,
Shanghai
,
China
Area served
China
Key people
  • Wei Yulin (Chairman)
  • Chen Qiyu (Vice-Chairman)
  • Li Zhiming (President)
Revenue CN¥227.069 billion (2015)
CN¥9.169 billion (2015)
CN¥3.761 billion (2015)
Total assets CN¥138.267 billion (2015)
Total equity CN¥30.052 billion (2015)
OwnerSinopharm Industrial Investment (56.79%)
ParentSinopharm Industrial Investment
SubsidiariesSinopharm CNMC
Footnotes / references
in a consolidated basis; equity and profit excluded minority interests; in Hong Kong Financial Reporting Standards[1]
Sinopharm Group Co., Ltd.
Simplified Chinese国药控股股份有限公司
Traditional Chinese國藥控股股份有限公司
Literal meaningSinopharm Holding Joint-Stock Limited Company
Sinopharm Group
Simplified Chinese国药控股
Traditional Chinese國藥控股
Literal meaningSinopharm Holding
Second alternative Chinese name
Simplified Chinese国控股份有限公司
Traditional Chinese國控股份有限公司

Sinopharm Group researches and develops, manufactures, distributes, and markets medicine and other healthcare products.[2] Sinopharm Group manages factories, research laboratories, traditional Chinese medicine plantations, and marketing and distribution networks that extend throughout China.

Its H shares were listed on the Hong Kong Stock Exchange in 2009,[3] with its IPO price of HK$16 per share. Sinopharm Group's subsidiary Sinopharm CNMC and Sinopharm Accord served as the A share counterpart of the company. However, the A share of Sinopharm Group itself was unlisted.

Sinopharm Group was ranked 829th in 2016 Forbes Global 2000 list.[4]

COVID-19 Vaccine development
Main article: BBIBP-CorV
See also: COVID-19 vaccine § Clinical trials started in 2020

BBIBP-CorV is one of two inactivated virus COVID-19 vaccine being developed by Sinopharm's parent company China National Pharmaceutical Group. As of December 2020, it is currently in Phase III trials in Argentina,[5] Bahrain,[6] Egypt,[7] Jordan,[8] Morocco,[9] Pakistan,[10] Peru,[11] and United Arab Emirates[12] with over 60,000 people.[13] On December 9, the UAE announced the official registration of BBICP-CorV after an interim analysis of the Phase III trials showed BBIBP-CorV to have a 86% efficacy against COVID-19 infection.[14]

Sinopharm's vaccine has emergency use authorization in Bahrain[15] and UAE.[16] BIBP-CorV could become a favorable option to vaccinate large parts of the developing world. While mRNA vaccines like BNT162b2 and MRNA-1273 showed higher efficacy of +90%, those present distribution challenges for some nations as they require deep-freeze facilities and trucks. BIBP-CorV could be transported and stored at normal refrigerated temperatures.[17]

See also

References
  1. "2015 Annual Report" (PDF). Sinopharm Group. Hong Kong Stock Exchange. 25 April 2016. Retrieved 22 November 2016.
  2. "Sinopharm Group Co. Ltd.: Private Company Information - Bloomberg". www.bloomberg.com. Retrieved 2017-07-27.
  3. Reuters Staff (2009-07-29). "China's Sinopharm gets OK for $1 bln HK IPO". Reuters. Retrieved 2020-11-14.
  4. "Sinopharm Group". Forbes. Retrieved 2020-11-14.
  5. "Clinical Trial to Evaluate the Efficacy, Immunogenicity and Safety of the Inactivated SARS-CoV-2 Vaccine (COVID-19) - Full Text View - ClinicalTrials.gov". clinicaltrials.gov. Retrieved 2020-12-13.
  6. Barrington, Lisa (2020-11-03). "Bahrain latest country to vaccinate frontline workers with COVID-19 shot". Reuters. Retrieved 2020-12-13.
  7. "Egypt to start receiving volunteers for COVID-19 vaccine trials". Egypt Independent. 2020-09-12. Retrieved 2020-12-13.
  8. "Jordan starts phase 3 trial of China's COVID-19 vaccine". Jordan Times. 2020-08-30. Retrieved 2020-12-13.
  9. "Morocco orders R-Pharm Covid-19 vaccine | The North Africa Post". northafricapost.com. Retrieved 2020-10-07.
  10. "Coronavirus vaccine should be available in Pakistan 'within 6-8 weeks'". www.geo.tv. Retrieved 2020-12-13.
  11. PERÚ, Empresa Peruana de Servicios Editoriales S. A. EDITORA. "Peru: 6,000 additional volunteers required for trials of Sinopharm's COVID-19 vaccine". andina.pe (in Spanish). Retrieved 2020-12-13.
  12. "Coronavirus: 15,000 register as volunteers for Covid-19 vaccine trial in UAE". The National. Retrieved 2020-12-13.
  13. Reuters Staff (2020-11-19). "China Sinopharm's coronavirus vaccine taken by about a million people in emergency use". Reuters. Retrieved 2020-12-09.
  14. "UAE: Ministry of Health announces 86 per cent vaccine efficacy". gulfnews.com. Retrieved 2020-12-13.
  15. Barrington, Lisa (3 November 2020). "Bahrain allows Sinopharm COVID-19 vaccine candidate use in frontline workers". Reuters. Retrieved 3 November 2020.
  16. Maxwell, Chris. "Coronavirus: UAE authorises emergency use of vaccine for frontline workers". The National. Retrieved 14 September 2020.
  17. "China State-Backed Covid Vaccine Has 86% Efficacy, UAE Says". Bloomberg.com. 2020-12-09. Retrieved 2020-12-09.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.